CSL Ltd. — Capital/Financing Update 2026

Feb 17, 2026

18 February 2026 Melbourne, Australia

CSL and Lilly enter Licensing Agreement for clazakizumab

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has entered into an exclusive licensing agreement with Eli Lilly and Company (“Lilly”) granting certain rights to develop and commercialise clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody.

Under the terms of the agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD).

CSL is advancing the ongoing POSIBIL6ESKD Phase 3 clinical trial (NCT05485961), which is evaluating the efficacy and safety of clazakizumab in patients with ESKD on dialysis at risk for major cardiovascular events.

Bill Mezzanotte, EVP and Head of Research and Development at CSL, commented: " This agreement marks a significant step forward in our mission to bring innovative therapies to patients worldwide. Clazakizumab is a promising therapeutic candidate with the potential to significantly impact the treatment landscape for various immuno-inflammatory and cardiovascular conditions. Lilly is another patient-focused organization, and we look forward to working with them to maximise the potential of this important medicine."

Developed by Vitaeris Inc. and acquired by CSL in 2020, clazakizumab is a monoclonal antibody that targets IL-6, a cytokine implicated in the pathogenesis of numerous diseases. IL-6 is a mediator of diverse biological processes, including immune regulation, hematopoiesis, and vascular inflammation. The overproduction of IL-6 is associated with chronic inflammation and has been observed in a range of medical conditions. By preventing the binding of IL-6 with its receptor, clazakizumab may mitigate the cascade that contributes to the symptoms and progression of various immuno-inflammatory conditions, potentially offering therapeutic benefits to patients with these conditions.

Under the terms of the agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with ESKD. Lilly will explore the development, global regulatory approval, and commercialisation of clazakizumab in additional indications. CSL will receive an upfront payment of $100 million and be eligible to receive potential clinical, regulatory and commercial milestone payments, as well as royalties on global net sales.

The closing of the transaction is subject to customary closing conditions, including all applicable regulatory clearances.

Page | 1

ASX Announcement

Authorised for lodgement by:

==> picture [101 x 76] intentionally omitted <==

Fiona Mead

Company Secretary

For further information, please contact:

==> picture [49 x 49] intentionally omitted <==

CSL Investors:

Jimmy Baker

Investor Relations CSL Limited P: +61 409 909 211 E: jimmy.baker@csl.com.au

==> picture [49 x 49] intentionally omitted <==

CSL Media:

Brett Foley Corporate Communications CSL Limited P: +61 461 464 708 E: brett.foley@csl.com.au

CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000

Page | 2

ASX Announcement